Advertisement
Astra Zeneca
Subscribe to Astra Zeneca

The Lead

MedImmune and Advaxis Partner on Immuno-Oncology Combination Clinical Trial

July 22, 2014 8:20 am | News | Comments

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.    

AstraZeneca Reveals Designs For New R&D Center & Corporate HQ In Cambridge, UK

July 18, 2014 9:08 am | by AstraZeneca | News | Comments

AstraZeneca today revealed the proposed designs for its new Global R&D Centre and Corporate...

AstraZeneca and Max Planck Institute to Create Satellite Chemistry Unit for Cardiovascular and Metabolic Diseases

July 8, 2014 8:47 am | News | Comments

AstraZeneca today announced an agreement with the Max Planck Institute of Molecular Physiology (...

Panel: Flu Spray Better Than Shots for Young Kids

June 26, 2014 8:30 am | by MIKE STOBBE, AP Medical Writer | News | Comments

When it comes to flu vaccines, a federal panel says a squirt in the nose is better than a shot...

View Sample

FREE Email Newsletter

AstraZeneca Licenses Synairgen's Asthma Therapy for $225M

June 13, 2014 8:43 am | News | Comments

Under the terms of the exclusive license agreement, AstraZeneca will pay Synairgen a $7.25 million up-front fee and potential development, regulatory and commercial milestones of up to $225 million. In addition, AstraZeneca will pay tiered royalties ranging from single-digit up to mid-teens on commercial sales. AstraZeneca will be responsible for future development costs.

Isis Pharmaceuticals Earns $15M from AstraZeneca for Initiation of Phase 1 Study of ISIS-AR Rx

June 10, 2014 8:21 am | News | Comments

Isis Pharmaceuticals announced today that AstraZeneca has initiated a Phase 1 clinical study of ISIS-ARRx in patients with cancer.  Isis earned a $15 million milestone payment associated with the clinical advancement of ISIS-ARRx. ISIS-ARRx is an antisense drug designed to treat patients with prostate cancer by inhibiting the production of the androgen receptor (AR).

AstraZeneca’s Novel Antibiotic Candidate AZD0914 Given Fast Track Status by FDA

June 3, 2014 8:04 am | News | Comments

AstraZeneca today announced that the FDA has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product (QIDP) and awarded its development program Fast Track status for the treatment of uncomplicated gonorrhea, which is increasingly resistant to existing antibiotics and poses a serious global public health threat.

Advertisement

Actavis Confirms Generic Onglyza Patent Challenge

May 28, 2014 9:05 am | News | Comments

Actavis has filed an Abbreviated New Drug Application with the FDA seeking approval to market Saxagliptin Hydrochloride Tablets, 2.5 mg and 5 mg. Actavis' ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb's Onglyza. 

Pfizer Pulls Plug on Push to Buy AstraZeneca

May 26, 2014 11:30 am | by Alex Veiga - AP Business Writer - Associated Press | News | Comments

Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history. The announcement came a week after AstraZeneca's board rejected a $119 billion buyout proposal from Pfizer.

Another AstraZeneca Shareholder Voices Criticism

May 21, 2014 2:13 pm | News | Comments

Another AstraZeneca shareholder has criticized the pharmaceutical company's handling of Pfizer's $119 billion takeover bid, saying Wednesday it was "arguably wrong" to reject it so quickly.          

AstraZeneca Shareholder Urges Pfizer Rethink

May 20, 2014 9:02 am | News | Comments

AstraZeneca shareholder Schroders has urged the pharmaceutical firm to reconsider its rejection of a takeover offer from U.S. drugmaker Pfizer. The fund manager, which holds a 2 percent stake in AstraZeneca, is the biggest shareholder to call publicly for renewed takeover talks.

AstraZeneca Board Rejects New Offer from Pfizer

May 19, 2014 7:59 am | by GREGORY KATZ, Associated Press; LINDA A. JOHNSON, Associated Press | News | Comments

The board of AstraZeneca has rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, a decision that has caused a sharp slide in the U.K. company's share price as many investors think it effectively brings an end to the protracted and increasingly bitter takeover saga.

Advertisement

As Pfizer Fights it Out in Britain, US Lawmakers are Making Their Move in the Long Game

May 16, 2014 9:03 am | by Brian Williamson, Managing Director, Jumpstart | Blogs | Comments

While British attention in the Pfizer-AstraZeneca takeover battle has been focused on clashes between MPs and Pfizer chief executive Ian Read, events have been unfolding across the Atlantic which could have an infinitely greater bearing on where the pharma giant eventually conducts its business.

Pfizer's Troubles Across the Pond

May 15, 2014 8:51 am | Videos | Comments

Why are British protectionists trying to block a proposed pharmaceutical merger?                             

Pfizer Chief Says Jobs Will Go in Takeover

May 13, 2014 1:48 pm | by DANICA KIRKA, Associated Press | News | Comments

Pfizer Inc.'s chief executive acknowledged Tuesday that a potential merger with AstraZeneca would lead to job losses — but promised to keep key research jobs in Britain as part of its $106 billion takeover bid.       

Lawmakers Press Pfizer CEO for Job Guarantees

May 13, 2014 7:58 am | by DANICA KIRKA, Associated Press | News | Comments

British lawmakers pressed the chief executive of Pfizer on Tuesday to guarantee jobs should the American company succeed in taking over London-based AstraZeneca, prodding him on whether he could be trusted to honor promises made as part of the bid.

Amgen and AstraZeneca Announce Positive Results from Phase 3 Psoriasis Study

May 12, 2014 8:52 am | News | Comments

Amgen and AstraZeneca announced that the Phase 3 AMAGINE-1TM study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses.       

Advertisement

UK PM Says He's Playing Fair on AstraZeneca Deal

May 12, 2014 8:26 am | by DANICA KIRKA, Associated Press | News | Comments

With fears growing that British jobs will be lost and the nation's science base undermined in the potential merger, Prime Minister David Cameron denied in a BBC interview that he was favoring the American company.      

AstraZeneca Starts Phase III Immunotherapy Study for MEDI4736 in Patients with Lung Cancer

May 8, 2014 9:07 am | News | Comments

The goal of the PACIFIC trial, the first study in the Phase III NSCLC program, is to evaluate progression free survival and overall survival of MEDI4736 compared to placebo in patients with locally advanced, unresectable NSCLC (Stage III).  

AstraZeneca Fends Off Pfizer with New Growth Plan

May 6, 2014 2:54 pm | by SYLVIA HUI, Associated Press | News | Comments

AstraZeneca has outlined plans to make sales jump over the next decade, an effort to persuade shareholders the drug maker can do well as an independent company, rather than get bought out by rival Pfizer.        

FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia

May 6, 2014 8:17 am | News | Comments

AstraZeneca today announced the FDA approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).   

Pfizer Mulls Options after AstraZeneca Snubs Offer

May 5, 2014 2:39 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Executives at drugmaker Pfizer Inc. say they're continuing to review options after British rival AstraZeneca PLC again rejected their proposal to buy the company, adding that Pfizer would prefer a friendly deal. The latest offer was valued at over $100 billion.

AstraZeneca Rejects Sweetened Pfizer Takeover Bid

May 2, 2014 6:36 am | by Danica Kirka - Associated Press - Associated Press | News | Comments

The board of pharmaceutical company AstraZeneca on Friday rejected drug maker Pfizer's sweetened takeover offer. Pfizer earlier in the day said it is offering 50 pounds ($84) a share in cash and stock, a 7.3 increase on a previous bid. The offer values AstraZeneca at $106 billion.

Pfizer Renews Its Bid for AstraZeneca

April 29, 2014 8:59 am | Videos | Comments

WSJ's Paul Vigna and Dana Cimilluca discuss Pfizer's bid to buy AstraZeneca.                                 

Pfizer Still Pursuing AstraZeneca After Second Rebuff

April 28, 2014 3:31 pm | by DANICA KIRKA, Associated Press; LINDA A. JOHNSON, Associated Press | News | Comments

Pfizer was turned down twice by AstraZeneca, but the maker of Viagra and Lipitor said Monday that its proposed $100 billion acquisition makes sense for shareholders of both companies, and it's considering its next steps.      

AstraZeneca Shares Soar on Pfizer Interest

April 28, 2014 5:31 am | by The Associated Press | News | Comments

AstraZeneca shares have jumped 15 percent in early trading after U.S. pharmaceutical firm Pfizer publicly disclosed details of a $100 billion bid approach. Pfizer said today that AstraZeneca rejected an initial approach in January valuing the company at about 59 billion pounds ($100 billion).

Japan Approves Forxiga® for Type 2 Diabetes

March 24, 2014 9:00 am | News | Comments

AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, as a once-daily oral treatment for type 2 diabetes.

AstraZeneca to Sell Alderley Park Site in Cheshire, UK

March 12, 2014 8:03 am | News | Comments

AstraZeneca today announced the sale of its Alderley Park site in Cheshire, UK, to Manchester Science Parks (MSP), a Greater Manchester based public-private partnership and science park operator.         

Dynavax to Receive $5.4M Milestone

March 4, 2014 8:19 am | News | Comments

Dynavax Technologies Corp. has announced a $5.4 million milestone payment from its collaborator, AstraZeneca.                         

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading